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Abstract
Purpose—To determine if there is a biologic rationale for using checkpoint inhibitor drugs 
targeting programmed cell death ligand 1 (PD-L1) and PD-L2 in the treatment of adenoid cystic 
carcinoma of the orbit.
Methods—Twenty-three cases of adenoid cystic carcinoma involving the orbit (13 primary 
lacrimal gland, 5 secondarily extending into the orbit, and 5 unspecified) were examined 
histopathologically. Immunohistochemistry for PD-L1, PD-L2, and CD8 was performed. Charts 
were reviewed for clinical correlations.
Results—Expression of PD-L1 and of PD-L2 was overall low in adenoid cystic carcinoma (mean 
expression 1.4?±0.9 of 5 for PD-L1, mean 0.83±1.1 of 5 for PD-L2), and tumor-infiltrating CD8-
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positive T-lymphocytes were sparse (mean 1.1?±0.51 of 3). Only 13 of the 23 (57%) cases 
expressed PD-L1 as a combined positive score ≥1 of cells. No associations were found between 
expression levels of these markers and patient sex, tumor site of origin, Tumor, Node, Metastasis 
stage, or patient outcome. A significant association was observed between stromal PD-L1 
expression and tumor histopathologic subtype (p = 0.05), and between tumor PD-L1 expression 
and prior exposure to radiation (p = 0.03).
Conclusions—Checkpoint inhibitor drugs may have limited impact in the treatment and clinical 
course of orbital adenoid cystic carcinoma based on the low frequency of CD8 infiltrate and low 
expression of PD-L1 and PD-L2. Pretreatment with radiation, however, may improve tumor 
response to checkpoint inhibitor drugs.
Checkpoint inhibitor drugs have been employed successfully in the treatment of many 
neoplasms, including cutaneous melanoma, renal cell carcinoma, non–small-cell lung 
carcinoma, squamous cell carcinomas of the head and neck, urothelial carcinoma, 
hepatocellular carcinoma, and Hodgkin lymphoma.1 Expression of programmed cell death 
ligand 1 (PD-L1) and PD-L2, degree of CD8-positive T-lymphocyte infiltration and tumor 
mutational burden have been found to predict tumor response to therapy with a class of 
drugs called immune checkpoint inhibitors (ICIs).2,3 Expression of these markers has also 
been found to correlate with prognosis for certain tumors.4 With regard to ocular adnexal 
malignancies, these markers are expressed in conjunctival invasive squamous cell 
carcinoma5,6 and sebaceous carcinoma.7–10
Adenoid cystic carcinoma (ACC) is an ocular adnexal malignancy with a different cell of 
origin and distinct behavior from squamous and sebaceous carcinomas. Despite extensive 
investigations, treatment of localized primary lacrimal gland ACC remains mostly limited to 
radiotherapy complementing surgery,11 but recurrent and metastatic disease remains a no 
man’s land devoid of any preferred and well-tested efficacious therapy. Studies investigating 
the expression of PD-L1 and PD-L2 in nonlacrimal gland ACC of the head and neck have 
found mostly low expression levels of these markers, suggesting a minimal role for 
checkpoint inhibitor drugs.12–17 This would suggest that checkpoint inhibitor drugs should 
correspondingly have a minimal role in the treatment of orbital ACCs. However, the results 
of studies from nonperiocular head and neck malignancies do not always translate directly to 
ocular adnexal malignancies.18 For example, lacrimal gland ACCs displayed a higher 
mutational burden than reported in ACCs of the head and neck,19,20 suggesting that there 
may be subtle differences between ACCs in these different areas.
The purpose of the current investigation was to assess the expression of PD-L1, PD-L2, and 
CD8-positive T-lymphocytes in ACC involving the orbit and ocular adnexa to determine 
whether there is a rationale for the use of ICIs in the treatment of primary ACC of the 
lacrimal gland or secondary tumors invading the orbit from the sinus. A secondary goal of 
this study was to determine whether any patient or tumor characteristics were associated 
with tissue PD-L1 or PD-L2 expression.
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This study was approved by the Institutional Review Board of the Massachusetts General 
Hospital and Partners Healthcare (Institutional Review Board #2014P000478) and is 
compliant with the Declaration of Helsinki and Health Insurance Portability and 
Accountability Act regulations. A search of the Massachusetts General Hospital (MGH) and 
Massachusetts Eye and Ear (MEE) pathology files using the terms “adenoid cystic 
carcinoma” and “orbit” was performed for cases submitted between 1990 and 2017. Forty 
cases were identified. Pathology reports, existing histopathologic slides, and tissue blocks 
were reviewed. Eighteen cases were found to have sufficient material in tissue blocks for 
immunohistochemical studies. An additional 5 cases of orbital ACC were supplied by the 
Wills Eye Hospital, bringing the total number of cases to 23. Thirteen cases from the MGH 
and MEE represented primary lacrimal gland ACC; 5 cases from MGH and MEE were ACC 
of the sinus or lacrimal sac with secondary extension or recurrence in the orbit. Clinical 
history, including prior radiation history, was available and reviewed for the 18 cases from 
MGH and MEE. The origin of the 5 cases from the Wills Eye Hospital was unspecified and 
no clinical history was available. Three normal lacrimal glands were selected as controls.
Ten tumors from MGH and MEE had no prior exposure to radiation. Nine of these were 
primary lacrimal gland tumors and one was of sinonasal origin with extension into the orbit.
Four tumors had exposure to radiation within a month prior to resection (ranging from 1 to 4 
weeks). The first was a primary lacrimal land tumor that had undergone an incisional biopsy 
and been treated with 8 Gray of radiation at an outside institution. The patient then 
transferred care to MEE and underwent surgical debulking of the residual tumor 4 weeks 
after radiation (specimen used in the current study), followed by an additional 64 Gray of 
postoperative radiation. The second case was a primary lacrimal gland tumor that underwent 
an incisional biopsy at an outside institution. The patient was then treated with 20 Gray of 
preoperative radiation followed by surgical excision of residual tumor 3 weeks after 
radiation (specimen used in the current study). This patient was treated with 54 Gray of 
postoperative radiation. The third case was a lacrimal gland tumor that underwent incisional 
biopsy and was treated with 72 Gray of radiation at an outside institution without definitive 
tumor excision. One year after the completion of radiation, the tumor increased in size. The 
tumor was treated at MEE with 20 Gray of radiation followed by surgical excision 1 week 
after radiation (specimen used in the current study); the tumor bed was exposed with 
postoperative brachytherapy. The fourth patient had a lacrimal gland tumor that was treated 
at an outside institution with subtotal resection followed by 71 Gray of radiation. The tumor 
recurred and was treated with 54 Gray of radiation followed by surgical excision 1.5 weeks 
after radiation (specimen used in the current study).
Four tumors had a remote history of radiation prior to resection. In all 4 cases, these were 
recurrent tumors. Three tumors were initially of sinonasal origin with recurrences in the 
orbit, while one was of lacrimal gland origin with a recurrence in the orbit. Two tumors were 
resected 6 years after prior radiation, 1 was resected 9 years after prior radiation, and 1 was 
resected 18 years after prior radiation.
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Five-micron paraffin sections were immunostained at the Massachusetts General Hospital’s 
Immunopathology Laboratory. The following antibodies were used: PD-L1 (rabbit 
monoclonal antibody clone E1L3N, 1:30 dilution, Cell Signaling Technology, Danvers, 
MA), PD-L2 (rabbit monoclonal antibody clone D7U8C, 1:100 dilution, Cell Signaling 
Technology, Danvers, MA), and CD8 (rabbit polyclonal antibody, #ab4055, 1:200 dilution, 
Abcam, Cambridge, MA).
Immunostained slides were scored by 2 pathologists using 2 scoring systems.5,21 The first 
scoring system finds more usefulness in research, as it reveals fine gradations in tissue 
expression of markers, but it is more time-consuming.5 The second scoring system, the 
combined positive score (CPS), is less time-consuming and is now commonly used for 
scoring PD-L1 expression in clinical trials and clinical practice; it is the scoring method 
used as a companion diagnostic for ICIs in various solid tumor types, including head and 
neck squamous cell carcinoma.21
As previously described, with the first scoring system, overall tissue expression of PD-L1 
and of PD-L2 was graded on a 0 to 5 scale. Zero indicated no positive cells; 1 rare individual 
positive cells; 2 infrequent small clusters of positive cells within or directly adjacent to 
tumor tissue; 3 a single large cluster, multiple smaller clusters, or a moderately dense diffuse 
infiltration; 4 indicated a single very large dense cluster, multiple large clusters or dense 
diffuse infiltration; and 5 designated staining of coalescing clusters or dense infiltration 
throughout the tumor tissue. For each sample, an assessment was also made on a 0 to 5 scale 
of whether the PD-L1 or PD-L2 immunostaining was present or absent in the tumor cells, 
stromal cells, or endothelial cells. Overall CD8 immunostaining was graded on a 0 to 3 
scale, with 0 indicating no infiltration: 1 indicating low, 2 moderate, and 3 high levels of 
infiltration. A separate 0 to 3 score was given for CD8 staining in the tumor and in the 
stroma.
The CPS was determined as follows: the proportion of all PD-L1-expressing cells (tumor, 
macrophage, and lymphocytes) over the total number of viable tumor cells × 100 was 
assessed. A sample was considered positive if the score was ≥1 and negative if the score was 
<1.21
Immunohistochemical results were analyzed about clinical characteristics, including patient 
sex, tumor origin, tumor size, patient outcome, history of radiation, and tumor 
histopathology. Statistical analyses were performed with TIBCO Statistica 13.5 (Palo Alto, 
CA). Cross-tabulation with the Fisher exact test was used for comparing categorical variable. 
Ordinal scores were compared between groups using 1-way analysis of variance. 
Relationships between ordinal variables were tested using Pearson and Spearman 
correlation. A p value of <0.05 was considered significant.
RESULTS
PD-L1, PD-L2, and CD8 Expression in Tumor and Stroma
Twenty-three cases of ACC involving the orbit were identified; 13 were of lacrimal gland 
origin, 5 were of sinonasal origin with extension or local recurrence in the orbit, and 5 were 
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orbital ACCs of unspecified primary location. Seventeen of 23 (74%) cases displayed 
tubular and/or cribriform morphology, while 6 were solid type (basaloid) or contained a 
component of solid type. Immunostaining for PD-L1 expression revealed low overall tissue 
expression levels of PD-L1 (mean 1.4±0.9) (Table 1). Similarly, PD-L1 expression was low 
in the different tissue subcompartments when graded on a 0 to 5 scale (mean 0.73±1.1 in 
tumor cells, mean 1.1±1.1 in the associated stroma, and mean 0.96±1.1 in endothelial cells) 
(Fig. 1A, B, see Fig. 1, Supplemental Digital Content, available at http://links.lww.com/IOP/
A218). With the CPS, which is a less stringent scoring system, PD-L1 expression was 
positive in 13 (57%) cases and negative in 10 (43%). The PD-L1 expression on tumor cells 
was membranous, with a predominance of expression on the apices of cells. Curiously, the 
current anti-PD-L1 antibody also prominently highlighted nerves, a likely artifact of this 
clone (Fig. 1C).
Expression levels of PD-L2 were similarly overall low (mean 0.83±1.13), with low 
expression levels in tumor cells (mean 0.22?±?0.85), low levels in the associated stroma 
(mean 0.87±1.2) and in endothelial cells (mean 0.04±0.21) (Table 1, Fig. 1D, F; see Fig. 1, 
Supplemental Digital Content, available at http://links.lww.com/IOP/A218). 
Immunostaining for CD8 revealed an overall low level of CD8-positive T-lymphocyte 
infiltration (mean 1.1±0.51). Lymphocytes were scarce in the tumor (mean 0.39±0.5) and 
more numerous in the associated stroma (mean 1.3±0.62) (Table 1, Fig. 1F, see Fig. 1, 
Supplemental Digital Content, available at http://links.lww.com/IOP/A218). Three tissue 
samples did not express any PD-L1, while 12 did not express any PD-L2. In summary, PD-
L1 and PD-L2 are expressed in ACC, but the degree of their expression is low.
Three normal human lacrimal glands were immunostained for the same markers as the 
tumors (Fig. 2A–C). Expression of PD-L1, PD-L2, and CD8-positive T-lymphocytes was 
similarly low in the control lacrimal gland tissue, but the number of samples was too small 
to draw any meaningful conclusions. Programmed cell death ligand 1 expression, when 
present, was membranous. The number of immunostained lacrimal glands was similarly too 
small to draw statistical conclusions about differences in PD-L1, PD-L2, and CD8 
expression of ACC compared with normal tissue.
Clinical Correlations With PD-L1, PD-L2, and CD8 Expression
The immunohistochemical data were examined within the context of the clinical 
characteristics including tumor origin, patient sex, tumor histopathology, exposure to 
preceding radiation, patient survival, and Tumor, Node, Metastasis stage to determine 
whether any relationships could be derived. Comparative analyses were performed for both 
the CPS and for the more finely graded score. Clinical data were available for 18 of the 23 
patients. It should be noted that due to small sample size, these analyses may be 
underpowered to detect certain relationships.
The mean age of the 18 patients at the time of initial tumor diagnosis was 40.1 years (± 19.7 
years) (Table 2). Nine patients were male and 9 were female. Thirteen tumors were of 
primary lacrimal gland origin, while 5 arose in the lacrimal sac or were of sinonasal origin 
with secondary extension into the orbit. Ten biopsies had been obtained prior to any 
radiation therapy; 4 biopsies were performed within a month of radiation (“immediately”), 
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while 4 were performed several years (ranging from 6 to 18 years) after preceding radiation. 
The radiation histories are detailed in the Materials and Methods section. Twelve tumors 
(67%) were at T2 stage or less, while 6 (33%) were at greater than T2 stage. Six patients 
died of their disease at a median of 12.9 years (standard deviation = 9.2 years) after 
completion of initial therapy. Eleven patients are alive at a median of 9.1 years (standard 
deviation = 7.1 years) after completion of initial therapy (Table 2). Of the 11 who are alive, 9 
have not experienced a recurrence or metastasis.
There were no associations found between PD-L1, PD-L2, or CD8 expression and tumor 
origin (lacrimal gland vs. nonlacrimal gland from surrounding sinuses), patient gender (male 
vs. female), Tumor, Node, Metastasis stage (≤T2 vs. >T2), or patient outcome (alive without 
recurrence vs. died or tumor recurred) for both the CPS and the more finely graded score 
(see Table 1, Supplemental Digital Content, available at http://links.lww.com/IOP/A219).
A relationship was identified between the expression of PD-L1 in the stroma and tumor 
histopathology. Tumors with tubular-cribriform histopathology tended to have a greater 
expression of stromal PD-L1 (mean 1.35, standard deviation 1.17) as compared with tumors 
that contained a solid component (mean 0.33, standard deviation 0.52; p = 0.05 (see Table 1, 
Supplemental Digital Content, available at http://links.lww.com/IOP/A219). No other 
relationships were identified between immunohistochemical markers and tumor 
histopathology.
A relationship was also identified between PD-L1 expression and tumor exposure to 
radiation with both the CPS and the more refined score. Tumors were separated into 3 
groups, the first without radiation prior to the biopsy, the second with radiation immediately 
preceding the biopsy (1–4 weeks), and the third with radiation years before the biopsy (6–18 
years). A significant relationship was identified with the PD-L1 CPS (p = 0.02) (see Table 1, 
Supplemental Digital Content, available at http://links.lww.com/IOP/A219). Eight of 10 
(80%) tumors without prior radiation had PD-L1 scores of <1, while 4 of 4 (100%) tumors 
with radiation years prior had PD-L1 expression of ≥1. Of the tumors that had radiation 
immediately prior to biopsy, 2 had PD-L1 expression of <1, while 2 had PD-L1 expression 
of ≥1. A similar association was found with the more refined scale. Tumor PD-L1 
expression was significantly greater in tumors that had radiation many years before biopsy 
(mean 2.25, standard deviation 1.71) as compared with tumors that had no prior radiation 
(mean 0.89, standard deviation 1.23), p = 0.03. No other significant relationships were 
identified between the expression of histopathologic markers and radiation history.
No relationships were observed between overall PD-L1 and PD-L2 expression or overall 
PD-L1 and CD8 expression; however, a correlation was observed between overall PD-L2 
and overall CD8 expression (see Table 2, Supplemental Digital Content, available at http://
links.lww.com/IOP/A220).
DISCUSSION
Despite surgical excision and radiotherapy, a significant number of patients with ACC 
develop local recurrences and metastases.11,22–24 Given the successes in treating other 
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malignancies with checkpoint inhibitor drugs, there has been hope that these drugs may find 
usefulness in the treatment of lacrimal gland and orbital ACC. Expression of checkpoint 
inhibitor markers such as PD-L1, tumor infiltration with CD8 T-lymphocytes, and tumor 
mutational burden have been discovered to correlate with tumor response to immunotherapy; 
PD-L1 expression has been used in deciding whether patients are eligible for participating in 
clinical trials with checkpoint inhibitor drugs.1,3,4,25–27
Our current study found that PD-L1 and PD-L2 are both expressed in very low levels in 
ACC involving the orbit (overall mean 1.4±0.9 of 5 for PD-L1, and overall mean 0.8±1.1 of 
5 for PD-L2). In addition, the number of CD8-positive infiltrating T-lymphocytes was low 
(overall mean 1.1±0.51 of 3). Occasional tumors focally expressed higher levels of PD-L1 or 
PD-L2. These results, in conjunction with the overall relatively low mutational burden of 
ACC,20,22,28,29 suggest that although a small subset of tumors may have the potential to 
respond to checkpoint inhibitors, most will not. The CPS for PD-L1, on the other hand, 
revealed that 57% of tumors had scores of =1, which in clinical practice would indicate that 
up to 57% could be eligible for treatment with checkpoint inhibitors.
Experience with checkpoint inhibitor drugs for nonophthalmic ACC has been greater with 
head and neck tumors; several studies have already examined the expression of PD-L1 and 
PD-L2 in such cases (Table 3). Three studies have examined the expression of both PD-L1 
and PD-L2,12–14 while 3 have explored the expression of PD-L1 alone.15–17 Four studies 
discovered no expression of PD-L1 in ACC tumor cells, while 2 identified very low levels of 
expression of PD-L1. These studies suggested a limited role for PD-L1 inhibitors with 
respect to ACC. The 3 studies that examined PD-L2 found positive expression in 45% to 
100% of samples. The latter suggested a possible role for PD-L2 or PD-1 inhibitors in the 
treatment of ACC. The results of the foregoing studies contrast with the results of our study 
in which higher expression of PD-L1 was seen over PD-L2. Possible explanations for the 
varying results include differences in the anti-PD-L1 and anti-PD-L2 antibodies used and the 
various scoring methods.
Many different scales have been used in the literature and in clinical trials to assess tumor 
expression levels of PD-L1 and PD-L2, some more complex than others. For PD-L1, the 
most widely used scale in clinical practice now is either the tumor proportion score or CPS, 
the latter of which grades the overall number of positive cells in both the tumor and 
surrounding stroma as ≥1 or <1.21 Although easily applied in clinical practice, this scale 
does not provide the detailed information of other scales5 that may be more advantageous 
for advancing basic research. For PD-L2, there is still significant variability in terms of 
which scales are used. For the purposes of the current study, a finely graded scale was 
applied to both PD-L1 and PD-L2 scoring, while also applying the commonly used CPS for 
PD-L1.
With regard to the current study, PD-L1, PD-L2, and CD8 expression and potential 
relationships to clinical characteristics such as patient gender, tumor origin (lacrimal gland 
vs. nonlacrimal gland sinonasal origin), Tumor, Node, Metastasis stage, patient outcome (no 
recurrence, local recurrence or metastasis), tumor histopathology (tubular-cribriform vs. any 
component of solid type), and radiation prior to biopsy (no radiation vs. radiation 
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immediately prior vs. history of radiation several years prior) were explored. The current 
study lacks the power to draw strong conclusions based on the small sample size (only 18 
patients had clinical data for analysis); however, several interesting trends were identified 
that may warrant closer examination in future studies.
The first association that warrants closer investigation is the relationship between tumor 
histopathologic subtype and PD-L1 expression. The current study found that PD-L1 
expression in the stroma of tumors with tubular-cribriform histopathology was greater than 
in the stroma of tumors with a solid-type component (p = 0.05) (see Table 1, Supplemental 
Digital Content, available at http://links.lww.com/IOP/A219). Tumors with tubular-
cribriform histopathology in general portend a better clinical course than those with solid-
type histopathology.23 This result may further indicate that tubular-cribriform tumors may 
respond better to checkpoint inhibitor drugs than solid-type tumors.
The second association gleaned from the current study warranting further investigation is the 
relationship between radiation and PD-L1 expression. Both the CPS and the more refined 
scale that the authors employed established that tumors that had previous radiation treatment 
displayed a significantly greater PD-L1 expression than tumors that had not had exposure to 
radiation (p = 0.01 and p = 0.02). Of interest was the fact that tumors that had been treated 
many years earlier with radiation maintained an increased level of PD-L1 expression. The 
relationship between PD-L1 expression and radiation is of clinical importance in patient 
treatment and is an area of active exploration in the Immuno-oncology field. Studies in non-
ACC human tissues and in animal models have demonstrated that PD-L1 and other immune 
checkpoints are transiently elevated after radiation and that this effect can be dose-
dependent.30,31 Moreover, combining radiation with checkpoint inhibitor drugs can result in 
a synergistic effect, allowing tumors that are usually minimally responsive to radiation or 
checkpoint inhibitors alone to be retarded and prolonging survival.32 Such findings suggest 
that tumors like ACC, which have inherently low mutational burden, low PD-L1 expression, 
and low levels of CD8 T-lymphocyte infiltration, might become responsive to ICIs if the 
drug is administered soon after pretreatment with radiation.
Clinical experience with ICIs in the treatment of ACC has been even more limited than 
immunohistochemical studies. The CTLA-4 inhibitor, ipilimumab, has been used to treat 
metastatic ACC in only 1 case33; the patient exhibited a slight clinical response to treatment 
but then developed a granulomatous dacryoadenitis. Programmed cell death ligand 1 
immunostaining was performed and revealed 0% membranous staining. In another case,34 
PD-1 inhibitor pembrolizumab was used in combination with radiotherapy to treat ACC of 
the parotid gland that had metastasized to the brain; the long-term outcome in this case is 
unknown.
Two patients with metastatic ACC have been treated with the PD-1 inhibitor pembrolizumab 
in a phase 1b clinical trial.35 KEYNOTE-028 is a large clinical study in which patients with 
many different metastatic tumors not responsive to other therapies have been enrolled. To 
qualify, patients had to have a PD-L1 positivity level of membranous staining in >1% of 
scorable cells in the tumor samples. Of 102 patients with head and neck tumors that were 
screened, 33 patients manifested PD-L1 positivity; 26 were eventually enrolled in the study. 
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Of those enrolled, only 2 patients had ACC. Three enrolled patients demonstrated a partial 
response to treatment, but they were not patients with ACC.35
A phase II clinical trial was performed at the Dana Farber Cancer Center and the MGH to 
assess the effects of pembrolizumab with or without radiation in ACC (NCT03087019; 
study number 16–609; Pembrolizumab With or Without Radiation in Patients with Recurrent 
or Metastatic Adenoid Cystic Carcinoma). The interim analysis revealed that 
pembrolizumab monotherapy or with hypofractionated radiation therapy was well tolerated.
36 No objective responses were observed; however, prolonged stable disease was achieved in 
a subset of patients.
The currently available clinical results reinforce the concept that checkpoint inhibitors may 
have a limited beneficial role in a small subset of patients with ACC. For most patients, 
however, other therapeutic avenues will need to be evaluated.37
The poor response of certain tumors such as ACC to immunotherapy may in part be due to 
the low number of associated inflammatory cells37 and the absence of immunogenic tumor 
antigens due to a low mutational tumor burden.19,20 Our study, along with others,12–16 has 
demonstrated low numbers of tumor-associated inflammatory cells in ACC. Some 
investigators have speculated that treatment with radiation may potentiate the effects of 
immunotherapies by increasing the inflammatory cell infiltrate,30–32 but this remains an 
unresolved issue and may depend on the dose of radiation administered.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Immunohistochemical staining for PD-L1, PD-L2, and CD8 in adenoid cystic carcinoma. A, 
PD-L1 positively immunnonstains the apical membranes of some tumor cells (arrow). B, 
PD-L1 positively immunostains the stromal cells (arrow) surrounding some tumors. In this 
case, the tumor cells do not express PD-L1. C, This anti-PD-L1 antibody also prominently 
highlights nerve fascicles in a number of the tumor samples examined (arrow). D, PD-L2 
positively immunostains the cytoplasm and membranes of some tumor cells (arrow). E, PD-
L2 positively immunostains clusters of S. In this case, the T do not express PD-L2. F, Rare 
CD8-positive T-lymphocytes are present infiltrating the tumor, but greater numbers are 
appreciated in the surrounding stroma (A–F, immunoperoxidase reaction, diaminobenzidine 
chromogen, hematoxylin counterstain, original magnification ×40, ×40, ×10, ×40, ×40, ×20, 
with additional optical magnification of ×3 for A–E and ×2 for F). PD-L, programmed cell 
death ligand; S, stromal cells; T, tumor cells.
Wolkow et al. Page 12














Immunohistochemical staining for PD-L1, PD-L2, and CD8 in normal lacrimal gland. A, 
PD-L1 positively immunostains occasional lacrimal gland acini in a membranous pattern 
(arrow). B, PD-L2 positively immunostains the cytoplasm and membranes of small clusters 
of stromal cells (arrow) distributed among the lacrimal gland acini. C, Low numbers of 
CD8-positive T-lymphocytes are scattered throughout the lacrimal gland (A–C, 
immunoperoxidase reaction, diaminobenzidine chromogen, hematoxylin counterstain, 
original magnification ×20, ×20, ×20, with additional ×3 optical magnification for A–C). 
PD-L, programmed cell death ligand.
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TABLE 1.
Expression of PD-L1 and PD-L2, and CD8 T-lymphocyte infiltration
Marker Degree of expression (mean ± standard deviation); n = 23 samples
PD-L1 overall* 1.4 ± 0.9 (n = 23); expression was 0 in 2 samples
 PD-L1 tumor 0.73 ± 1.1
 PD-L1 stroma 1.1 ± 1.1
 PD-L1 endothelium 0.96 ± 1.1
PD-L2 overall† 0.83 ± 1.1 (n = 23); expression was 0 in 4 samples
 PD-L2 tumor 0.22 ± 0.85
 PD-L2 stroma 0.87 ± 1.2
 PD-L2 endothelium 0.04 ± 0.21
CD8 overall‡ 1.1 ± 0.51 (n = 23); expression was 0 in 2 samples
 CD8 tumor 0.39 ± 0.5
 CD8 stroma 1.3 ± 0.62
Combined positive score Degree of expression (mean ± standard deviation); n = 23 samples
PD-L1 ≥ 1 57% (n = 13 samples)
PD-L1 < 1 43% (n = 10 samples)
*
PD-L1 scored on a 0–5 scale.
†
PD-L2 scored on a 0–5 scale.
‡
CD8 scored on a 0–3 scale.
PD-L, programmed celi death ligand.
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TABLE 2.
Patient clinical characteristics (n = 18)
Clinical characteristic
Age at diagnosis 40.1 ± 19.7
Sex
 Male 9 (50%)
 Female 9 (50%)
Tumor origin
 Lacrimal gl and 13 (72%)
 Sinonasal or lacrimal sac 5 (28%)
Timing of biopsy
 Before radiation 10 (56%)
 Immediately after radiation (1–4 weelcs) 4 (22%)
 Years after radiation (6–18 years) 4 (22%)
Tumor stage
 T2 or less 12 (67%)
 Greater than T2 6 (33%)
Patient survival (years)
 Died 12.9 years median (standard deviation 9.2 years; n = 6)
 Alive (with or without recurrence) 9.1 years median (standard deviation 7.1 years; n = 11)
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